PRECISION™ AI Neuro‑Phenomic platform for neurological drug discovery
We integrate high‑content imaging, multi‑omics, and AI‑driven deep phenomics to discover and validate disease‑modifying therapies for CMT1A and other neurodegenerative disorders.
Built on proprietary CMT1A cellular and in vivo models, our platform turns complex neurobiology into actionable digital phenomic signatures.
We develop precision therapies and Digital AI Neuro‑Phenomic platforms for CMT1A and other neurodegenerative disorders.
By combining real disease biology with high‑content imaging, multi‑omics, and AI, we aim to reduce translational failure and unlock first‑in‑class neurotherapeutics.
Our proprietary PRECISION™ HCS/HTS platform is built on disease‑relevant CMT1A and peripheral nerve models, capturing rich high‑content imaging and functional readouts. These "real biological data" power our Digital AI Neuro‑Phenomic platform, which integrates multi‑omics and AI to generate actionable phenomic signatures for target de‑risking and drug candidate validation.
We work with biopharma and innovative biotech teams to apply our Digital AI Neuro‑Phenomic platform to high‑risk neuro programs. We are also building a team at the intersection of neuroscience, AI, and high‑content biology—join us to shape the future of precision neurotherapeutics.